Consumers are exposed to a diversity of chemicals in all areas of life. Air, water, soil and food are all unavoidable components of the human environment. Each of those elements influences the quality of human life, and each of them may be contaminated. We are exposed to toxic or potentially toxic compounds in many ways in our daily lives and toxicology is clearly a subject of great importance for society. This becomes apparent when we look at the types of poisons and the ways in which we are exposed to them. Indeed, the categories cover virtually all the chemicals one might expect to encounter in the environment. After consideration of this, one might well ask “Are all chemicals toxic?” Phrase as an answer: “There are no safe chemicals, only their safe use”. Xenobiotics are defined here as those compounds, both organic and inorganic, produced by human beings and introduced into the environment, as well as into the food chain at concentrations that cause undesirable effects. Xenobiotics in the food chain are monitored in two forms: by testing – the objective of which is to discover unsuitable foodstuffs in the consumer’s network, and by monitoring – to obtain objective information about environmental components contamination and to harmlessness health of available foodstuffs.
The main objective of the study was to find out prevalence of depression and anxiety symptoms in the population of patients with AMI with ST-segment elevation (STEMI), treated with primary PCI (pPCI). Secondary target indicators included the incidence of sleep disorders and loss of interest in sex. The project enrolled 79 consecutive patients with the first AMI, aged <80 years (median 61 years, 21.5% of women) with a follow-up period of 12 months. Symptoms of depression or anxiety were measured using the Beck Depression Inventory II tests (BDI-II, cut-off value ≥14) and Self-Rating Anxiety Scale (SAS, cut-off ≥ 45) within 24 hours of pPCI, before the discharge, and in 3, 6 and 12 months). Results with the value p<0.05 were considered as statistically significant. The BDI-II positivity was highest within 24 hours after pPCI (21.5%) with a significant decline prior to the discharge (9.2%), but with a gradual increase in 3, 6 and 12 months (10.4%; 15.4%; 13.8% respectively). The incidence of anxiety showed a relatively similar trend: 8.9% after pPCI, and 4.5%, 10.8% and 6.2% in further follow-up. Patients with STEMI treated by primary PCI have relatively low overall prevalence of symptoms of depression and anxiety. A significant decrease in mental stress was observed before discharge from the hospital, but in a period of one year after pPCI, prevalence of both symptoms was gradually increasing, which should be given medical attention.